0.7675
price down icon2.23%   -0.0175
 
loading
Caribou Biosciences Inc stock is traded at $0.7675, with a volume of 1.01M. It is down -2.23% in the last 24 hours and down -30.23% over the past month. Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$0.785
Open:
$0.7411
24h Volume:
1.01M
Relative Volume:
0.83
Market Cap:
$71.38M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-0.5257
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-18.27%
1M Performance:
-30.23%
6M Performance:
-58.96%
1Y Performance:
-83.09%
1-Day Range:
Value
$0.7008
$0.784
1-Week Range:
Value
$0.7008
$0.9431
52-Week Range:
Value
$0.7008
$4.665

Caribou Biosciences Inc Stock (CRBU) Company Profile

Name
Name
Caribou Biosciences Inc
Name
Phone
510-982-6030
Name
Address
2929 7TH STREET, SUITE 105, BERKELEY
Name
Employee
147
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CRBU's Discussions on Twitter

Compare CRBU with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CRBU
Caribou Biosciences Inc
0.7675 71.38M 34.48M -102.07M -104.90M -1.46
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-03-24 Downgrade Evercore ISI Outperform → In-line
Nov-08-23 Initiated Cantor Fitzgerald Neutral
Oct-31-23 Initiated Evercore ISI Outperform
Jul-11-23 Initiated Truist Buy
Feb-18-22 Initiated RBC Capital Mkts Outperform
Dec-01-21 Initiated Oppenheimer Outperform
Nov-30-21 Initiated H.C. Wainwright Buy
Nov-15-21 Upgrade Citigroup Neutral → Buy
Aug-17-21 Initiated BofA Securities Buy
Aug-17-21 Initiated Citigroup Neutral
Aug-17-21 Initiated SVB Leerink Outperform
View All

Caribou Biosciences Inc Stock (CRBU) Latest News

pulisher
03:47 AM

Thrivent Financial for Lutherans Acquires 79,636 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World

03:47 AM
pulisher
Apr 04, 2025

Caribou Biosciences stock hits 52-week low at $0.71 By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Caribou Biosciences stock hits 52-week low at $0.71 - Investing.com Australia

Apr 04, 2025
pulisher
Apr 03, 2025

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

Apr 03, 2025
pulisher
Apr 01, 2025

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

Apr 01, 2025
pulisher
Mar 30, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect - markets.businessinsider.com

Mar 30, 2025
pulisher
Mar 27, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation - Markets Insider

Mar 27, 2025
pulisher
Mar 26, 2025

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus Target Price from Analysts - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Caribou Biosciences stock hits 52-week low at $0.95 By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Caribou Biosciences stock hits 52-week low at $0.95 - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation - Markets Insider

Mar 25, 2025
pulisher
Mar 22, 2025

Caribou Biosciences’ (CRBU) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out - Markets Insider

Mar 20, 2025
pulisher
Mar 20, 2025

Caribou Biosciences’ SWOT analysis: CRISPR pioneer’s stock faces critical juncture - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Caribou Biosciences’ SWOT analysis: CRISPR pioneer’s stock faces critical juncture By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19 - Marketscreener.com

Mar 20, 2025
pulisher
Mar 19, 2025

US Bancorp DE Buys 26,467 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect - Markets Insider

Mar 18, 2025
pulisher
Mar 17, 2025

Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock - Investing.com India

Mar 17, 2025
pulisher
Mar 16, 2025

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider

Mar 16, 2025
pulisher
Mar 15, 2025

Analysts Remain Bullish on Caribou Biosciences (CRBU) Despite Ongoing Slump in its Shares - Markets Insider

Mar 15, 2025
pulisher
Mar 13, 2025

Caribou Biosciences stock hits 52-week low at $1 By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Caribou Biosciences stock hits 52-week low at $1 - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation - Markets Insider

Mar 13, 2025
pulisher
Mar 13, 2025

CRBU FY2029 EPS Reduced by Brookline Capital Management - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Caribou Biosciences Brass Face Investor's Clinical Trials Suit - Law360

Mar 12, 2025
pulisher
Mar 12, 2025

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

Caribou Biosciences Advances CRISPR Therapies Amid Financial Challenges - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation - Markets Insider

Mar 11, 2025
pulisher
Mar 11, 2025

RBC Cuts Price Target on Caribou Biosciences to $11 From $14, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 11, 2025
pulisher
Mar 10, 2025

Caribou Biosciences reports Q4 EPS (39c), consensus (42c) - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Caribou Biosciences shares rise on narrower-than-expected Q4 loss By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Caribou Biosciences shares rise on narrower-than-expected Q4 loss - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Caribou Biosciences, Inc. SEC 10-K Report - TradingView

Mar 10, 2025
pulisher
Mar 10, 2025

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 10, 2025
pulisher
Mar 10, 2025

Caribou Biosciences, Inc. Anticipates Clinical Data from CB-010 and CB-011 in H1 2025 Amidst Advancements in Hematologic Malignancies and Autoimmune Disease Therapies - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - The Bakersfield Californian

Mar 10, 2025
pulisher
Mar 08, 2025

Caribou Biosciences, Inc. Sued for Securities Law ViolationsI - GuruFocus.com

Mar 08, 2025
pulisher
Mar 07, 2025

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Mar 07, 2025
pulisher
Mar 04, 2025

Caribou Biosciences Leaders Overhyped Cancer Therapy, Suit Says - Bloomberg Law News

Mar 04, 2025
pulisher
Mar 03, 2025

Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on Monday - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus PT from Analysts - Defense World

Mar 01, 2025

Caribou Biosciences Inc Stock (CRBU) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):